Press Release June 29, 2021

Tvardi Therapeutics Raises $74 Million in Series B Financing

The Life Sciences and Intellectual Property teams advised Tvardi Therapeutics, Inc. on intellectual property and regulatory due diligence matters related to its $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with continued support and participation by existing investors, including Sporos Bioventures.

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases.

Proceeds from this financing will be used to advance Tvardi’s product candidates through multiple clinical data readouts in mid-stage trials for cancer and fibrosis. The company’s lead product, TTI-101, is currently being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. To date, TTI-101 has been well-tolerated and demonstrated multiple durable radiographic objective responses in cancer patients treated with TTI-101 monotherapy.

The Goodwin team consisted of Sabrina Poulos and Bonnie Choi (Intellectual Property), and Nicholas Mitrokostas and Alexander Varond (FDA).

For more details, read the press release.